| | | 占用方与上市 | | 2025 年期初 | 2025 年半年 | 2025 年半年 | 2025 | 年半年 2025 | 年半年 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金 | 资金占用方名称 | 公司的关联关 | 上市公司核算 | 往来 | 度往来累计 | 度往来资金 | 度偿还 | | 度期末往来 | 占用形成 | 占用性质 | | 占用 | | | 的会计科目 | | 发生金额(不 | 的利息(如 | 累计发生金 | | | 原因 | | | | | 系 | | 资金余额 | 含利息) | 有) | 额 | | 资金余额 | | | | 控股股东、实 | | | | | | | | | | | | | 际控制人及其 | | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | | | - | | 前控股股东、 | | | | | | | | | | | ...

第六届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 证券代码：300030 证券简称：阳普医疗 公告编号：2025-036 阳普医疗科技股份有限公司 一、审议通过《2025 年半年度报告》及摘要 特此公告。 阳普医疗科技股份有限公司监事会 阳普医疗科技股份有限公司（以下简称"公司"）第六届监事会第十三次会 议（以下简称"本次会议"）通知已于 2025 年 8 月 1 日以电子邮件方式送达全体 监事。本次会议于 2025 年 8 月 13 日在公司会议室以现场与通讯相结合的方式召 开。本次会议应到监事 3 人，实到监事 3 人，公司高级管理人员列席了本次会议。 本次会议的内容以及召集、召开的方式、程序均符合《公司法》和《公司章程》 的规定。本次会议由监事会主席方秋鹏先生主持。与会监事经过充分的讨论，通 过以下决议： 2025 年 8 月 13 日 公司监事会在全面审核和了解公司 2025 年半年度报告全文及摘要后，认为公 司 2025 年半年度报告全文及摘要真实、准确、完整地反映了公司的实际经营状况 和经营成果，认为其陈述事项真实 ...

本公司及全体董事会成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）第六届董事会第十四次会 议（以下简称"本次会议"）通知已于 2025 年 8 月 1 日以电子邮件方式送达全体 董事。本次会议于 2025 年 8 月 13 日在公司会议室以现场与通讯相结合的方式召 开。本次会议应到董事 9 人，实到董事 9 人，公司监事和高级管理人员列席了本 次会议。本次会议的内容以及召集、召开的方式、程序均符合《公司法》和《公 司章程》的规定。本次会议由董事长杨涛先生主持。与会董事经过充分的讨论， 通过以下决议： 一、审议通过《2025 年半年度报告》及摘要 证券代码：300030 证券简称：阳普医疗 公告编号：2025-035 阳普医疗科技股份有限公司 第六届董事会第十四次会议决议公告 公司董事会在全面审核和了解公司 2025 年半年度报告全文及摘要后，认为公 司 2025 年半年度报告全文及摘要真实、准确、完整地反映了公司的实际经营状况 和经营成果，认为其陈述事项真实、准确、完整，不存在应披露而未披露事项， 不存在任何虚假记载、误导性陈述或者 ...

[Section 1 Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Section%201%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides definitions for key terms, company names, and medical device terminology to ensure clear understanding of the report [Important Notice](index=2&type=section&id=Important%20Notice) The Board of Directors, Supervisory Board, and senior management guarantee the accuracy and completeness of the semi-annual report, with no plans for cash dividends or bonus shares - The Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, assuming individual and joint legal responsibility[3](index=3&type=chunk) - Company head Yang Tao, chief accountant Yan Hongyu, and head of accounting Li Ning declare the financial report to be true, accurate, and complete[3](index=3&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[4](index=4&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) The report's clear table of contents covers eight main chapters, including company overview, management discussion, and financial reports - The report's table of contents includes eight main chapters, covering comprehensive information on company operations, finance, governance, and significant matters[6](index=6&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines key terms, company and subsidiary names, medical device terminology, and the reporting period for clarity - The definitions section clarifies the names of the company and its subsidiaries, such as Improve Medical, Ruida Medical, and Improve Jingcheng[11](index=11&type=chunk) - Several medical device and diagnostic terms are explained, including LIS (Laboratory Information System), CTC (Circulating Tumor Cells), and Thromboelastography, aiding business understanding[11](index=11&type=chunk) - The reporting period is defined as January 1, 2025, to June 30, 2025[12](index=12&type=chunk) [Section 2 Company Profile and Key Financial Indicators](index=7&type=section&id=Section%202%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides the company's basic information, contact details, key financial data, and non-recurring gains and losses, outlining its profile and financial performance [I. Company Profile](index=7&type=section&id=I.%20Company%20Profile) Improve Medical Instruments Co.,Ltd. (stock code: 300030) is listed on the Shenzhen Stock Exchange, with Yang Tao as its legal representative - The company's stock abbreviation is “Improve Medical”, stock code “**300030**”, listed on the Shenzhen Stock Exchange[14](index=14&type=chunk) - The company's legal representative is Yang Tao[14](index=14&type=chunk) [II. Contact Persons and Information](index=7&type=section&id=II.%20Contact%20Persons%20and%20Information) The company's Board Secretary is Yu Wei, Securities Affairs Representative is Zhuang Xuhua, with contact addresses in Zhuhai and Guangzhou - The Board Secretary is Yu Wei, and the Securities Affairs Representative is Zhuang Xuhua[15](index=15&type=chunk) - Company contact addresses include Room 801-8017, Hengqin International Business Center, No. 3000 Huandao East Road, Hengqin New Area, Zhuhai, and No. 102 Kaiyuan Avenue, Science City, Guangzhou Economic and Technological Development Zone[15](index=15&type=chunk) [III. Other Information](index=7&type=section&id=III.%20Other%20Information) During the reporting period, there were no changes in the company's contact information, disclosure locations, or registration status - The company's registered address, office address, website, and email address remained unchanged during the reporting period[16](index=16&type=chunk) - Information disclosure and filing locations remained unchanged during the reporting period[17](index=17&type=chunk) - The company's registration status remained unchanged during the reporting period[18](index=18&type=chunk) [IV. Key Accounting Data and Financial Indicators](index=8&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Revenue decreased by **21.22%** year-on-year, but net profit attributable to shareholders significantly grew by **389.40%**, with basic EPS turning positive Key Accounting Data and Financial Indicators (Current Period vs. Prior Year) | Indicator | Current Period (RMB) | Prior Year (RMB) | Current Period Change from Prior Year | | :--- | :--- | :--- | :--- | | Operating Revenue | 230,956,513.82 | 293,161,345.69 | -21.22% | | Net Profit Attributable to Shareholders of Listed Company | 15,266,563.13 | -5,275,309.54 | 389.40% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains/Losses) | 15,179,785.61 | -8,804,817.70 | 272.40% | | Net Cash Flow from Operating Activities | 17,107,755.47 | 17,229,405.33 | -0.71% | | Basic Earnings Per Share (RMB/share) | 0.05 | -0.02 | 350.00% | | Diluted Earnings Per Share (RMB/share) | 0.05 | -0.02 | 350.00% | | Weighted Average Return on Net Assets | 2.48% | -0.73% | 3.21% | | **Period-End Indicators** | **Current Period-End (RMB)** | **Prior Year-End (RMB)** | **Period-End Change from Prior Year-End** | | Total Assets | 1,118,593,526.11 | 1,244,146,915.63 | -10.09% | | Net Assets Attributable to Shareholders of Listed Company | 622,005,052.06 | 606,734,458.26 | 2.52% | [V. Differences in Accounting Data Under Domestic and International Accounting Standards](index=8&type=section&id=V.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20International%20Accounting%20Standards) During the reporting period, there were no differences in net profit or net assets between financial reports disclosed under international/overseas and Chinese accounting standards - The company's financial reports showed no differences in net profit and net assets between International Accounting Standards and Chinese Accounting Standards during the reporting period[20](index=20&type=chunk) - The company's financial reports showed no differences in net profit and net assets between overseas accounting standards and Chinese Accounting Standards during the reporting period[21](index=21&type=chunk) [VI. Non-Recurring Gains and Losses and Amounts](index=8&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) Total non-recurring gains and losses amounted to **RMB 86,777.52**, primarily from non-current asset disposal, government grants, and fair value changes Non-Recurring Gains and Losses and Amounts | Item | Amount (RMB) | Description | | :--- | :--- | :--- | | Gains/losses on disposal of non-current assets (including reversal of asset impairment provisions) | -902,707.04 | | | Government grants recognized in current profit/loss (excluding those closely related to normal operations, compliant with national policies, enjoyed by fixed standards, and with a continuous impact on company profit/loss) | 323,239.99 | | | Gains/losses from changes in fair value of financial assets and liabilities held by non-financial enterprises, and gains/losses from disposal of financial assets and liabilities, excluding effective hedge accounting related to normal business operations | 227,669.04 | | | Reversal of impairment provisions for receivables subject to individual impairment testing | 1,407.31 | | | Other non-operating income and expenses apart from the above | 462,777.05 | | | Less: Income tax impact | -44,657.14 | | | Impact on minority interests (after tax) | 70,265.97 | | | Total | 86,777.52 | | - The company has no other profit/loss items meeting the definition of non-recurring gains/losses, nor has it classified items listed in 'Interpretive Announcement No. 1 on Information Disclosure by Companies Issuing Securities to the Public – Non-Recurring Gains and Losses' as recurring gains/losses[24](index=24&type=chunk) [Section 3 Management Discussion and Analysis](index=10&type=section&id=Section%203%20Management%20Discussion%20and%20Analysis) This section analyzes the company's main businesses, core competencies, operating performance, financial position, investments, and risks, providing a comprehensive operational overview [I. Main Businesses Engaged by the Company During the Reporting Period](index=10&type=section&id=I.%20Main%20Businesses%20Engaged%20by%20the%20Company%20During%20the%20Reporting%20Period) The company specializes in R&D, production, and sales of medical devices and IVD products, leading in pre-analytical sample variation control and expanding into precision medicine - The company is a high-tech enterprise with nearly three decades in pre-analytical sample variation control, a leader in domestic venous blood collection, and ranks among the top globally[33](index=33&type=chunk) - Starting with vacuum blood collection systems, the company's IVD-based products and services cover the entire clinical laboratory sample collection and data management chain, extending to molecular diagnostics-focused tumor companion diagnostics[33](index=33&type=chunk) - The company has strategically entered precision medicine and third-party special testing, focusing on early tumor screening and companion diagnostics, developing related products, technologies, and services[34](index=34&type=chunk) [(I) Industry Overview](index=10&type=section&id=%28I%29%20Industry%20Overview) The medical device market is expanding, with global scale projected to exceed **$650 billion by 2027** and China's market reaching **RMB 1.82 trillion by 2032** - The global medical device market is projected to exceed **$650 billion by 2027**, with a CAGR of **5.3%**[26](index=26&type=chunk) - China's medical device market is expected to grow at a CAGR of **10.2%** from 2021-2025 and **5.6%** from 2025-2032, potentially reaching **RMB 1.82 trillion by 2032**[26](index=26&type=chunk) - In 2023, China's medical device industry revenue reached **RMB 1.31 trillion**, with a CAGR of **10%** from 2014-2023[26](index=26&type=chunk) - The global IVD market is estimated at **$109.2 billion in 2024**, projected to reach **$135.1 billion by 2029**; China's IVD market is estimated at **$6.1 billion in 2024**, with an **8.0%** annual growth rate, reaching **$8.9 billion by 2029**[29](index=29&type=chunk)[30](index=30&type=chunk) - The global molecular diagnostics market is projected to reach **$37.5 billion by 2026**, with a CAGR of **19.8%** from 2023-2026[31](index=31&type=chunk) - China's precision medicine market is expected to grow at an average annual rate of approximately **12%** from 2023-2028, exceeding **RMB 400 billion by 2028**[32](index=32&type=chunk) [(II) Company Position](index=11&type=section&id=%28II%29%20Company%20Position) The company is a leading domestic enterprise in venous blood collection and the only Chinese vacuum blood collection tube manufacturer registered with the US FDA - The company is a high-tech enterprise with nearly three decades in pre-analytical sample variation control, a leader in domestic venous blood collection, and ranks among the top globally[33](index=33&type=chunk) - The company is the only domestic vacuum blood collection tube manufacturer registered with the US FDA, participating in national and industry standard setting for products like vacuum blood collection tubes and thromboelastography[33](index=33&type=chunk) - The company has strategically entered precision medicine and third-party special testing, focusing on early tumor screening and companion diagnostics, aiming to become a domestic and global leader in these fields[34](index=34&type=chunk)[35](index=35&type=chunk) [(III) Main Businesses and Products](index=12&type=section&id=%28III%29%20Main%20Businesses%20and%20Products) The company's main businesses include smart laboratory products, IVD products, testing services, and IT solutions, with a focus on precision medicine - Smart laboratory products focus on secure and intelligent venous blood collection systems, specialized vacuum blood collection tubes for various tests, and offer intelligent blood collection management solutions (IBMS) and integrated smart laboratory solutions (AIM-LIS)[37](index=37&type=chunk)[38](index=38&type=chunk)[42](index=42&type=chunk) - The IVD product line is led by the thromboelastograph, an original product developed in collaboration with Duke University, holding exclusive invention patents, with the fully automatic thromboelastograph Xingyang XY-1200 having obtained a national Class II medical device registration certificate[44](index=44&type=chunk)[46](index=46&type=chunk)[48](index=48&type=chunk) - Testing services, provided by Guangzhou Improve Medical Laboratory Co., Ltd., focus on tumor screening and diagnosis across the entire cancer lifecycle, offering advanced detection services such as NGS, ctDNA, and CTC[50](index=50&type=chunk)[51](index=51&type=chunk) - Information technology products include core basic information systems for smart hospitals (HIS&EMR systems), hospital information platforms, and integrated smart laboratory solutions, serving over **200** tertiary hospital clients in Guangdong Province[52](index=52&type=chunk) [(IV) Business Model](index=16&type=section&id=%28IV%29%20Business%20Model) The company employs centralized procurement and make-to-order production, with a quality management system adhering to international standards, utilizing direct and distribution sales channels - The company implements a centralized procurement model through its procurement department, selecting qualified suppliers via evaluation and performance management processes[57](index=57&type=chunk) - The company adopts a make-to-order, batch production approach, establishing an integrated enterprise operation management system based on 'process/workflow management' and 'risk management' principles, incorporating international standards such as ISO 9001, ISO 13485, MDR, and IVDR[58](index=58&type=chunk)[59](index=59&type=chunk)[60](index=60&type=chunk) - The company has established a marketing and service network covering most provinces and cities nationwide and over **100** countries and regions globally, combining direct and distribution sales models while strengthening end-user control[61](index=61&type=chunk) - The domestic market focuses on developing hospitals below tertiary level and third-party medical testing laboratories; the overseas market follows a 'key breakthrough, leading by example' principle, expanding through exhibitions and surveys[62](index=62&type=chunk)[63](index=63&type=chunk) [(V) Key Performance Drivers](index=17&type=section&id=%28V%29%20Key%20Performance%20Drivers) Performance was driven by focusing on core business, cost reduction, efficiency improvement, and governance upgrades, alongside continuous R&D and market expansion - The company focused on its core business, closing, suspending, merging, or transferring non-core and inefficient investment projects, strengthening management and internal controls, and improving working capital efficiency and asset quality[64](index=64&type=chunk) - The company continued R&D investment, with its wholly-owned subsidiary Guangzhou Improve Medical Instruments Co., Ltd. obtaining a medical device registration certificate for its independently developed Functional Fibrinogen Detection Reagent Kit (Coagulation Method), expanding the detection types for thromboelastograph diagnostic products[64](index=64&type=chunk)[65](index=65&type=chunk) - The company actively participated in major domestic and international exhibitions and industry conferences, such as Medlab Middle East 2025 in Dubai, the Western Veterinary Conference in the US, and EUROMEDLAB 2025 in Europe, effectively enhancing its international brand influence and promoting technological cooperation[66](index=66&type=chunk) [(VI) Medical Device Registration Certificates](index=18&type=section&id=%28VI%29%20Medical%20Device%20Registration%20Certificates) As of June 30, 2025, the company holds **50** medical device registration certificates (39 China, 11 international), covering NMPA, FDA, CE, and Canada Medical Device Registration Certificate Statistics | Indicator | Quantity (Units) | | :--- | :--- | | Number of Medical Device Registration Certificates as of June 30, 2025 | 50（China 39, International 11） | | Number of New Medical Device Registration Certificates from January 1 to June 30, 2025 | 1（China 1, International 0） | | Number of Expired Medical Device Registration Certificates from January 1 to June 30, 2025 | 6（China 6, International 0） | - The company holds multiple NMPA registration certificates, including for disposable vacuum blood collection tubes, thromboelastographs, fully automatic thromboelastographs, and functional fibrinogen detection reagent kits[72](index=72&type=chunk)[73](index=73&type=chunk)[74](index=74&type=chunk)[75](index=75&type=chunk) - The company's products have obtained registration certifications from multiple international markets, including US FDA, EU CE, and Canada, demonstrating compliance with high international standards for product quality and management systems[76](index=76&type=chunk)[77](index=77&type=chunk)[78](index=78&type=chunk)[79](index=79&type=chunk)[80](index=80&type=chunk) [II. Analysis of Core Competencies](index=24&type=section&id=II.%20Analysis%20of%20Core%20Competencies) Core competencies include brand, product, and R&D advantages, positioning the company as a leader in pre-analytical sample variation control with international certifications and patents - The company has over two decades of expertise in pre-analytical sample variation control technology and related product R&D, being a domestic pioneer and leader, and the only Chinese vacuum blood collection tube manufacturer registered with the FDA, possessing a broad base of benchmark hospital clients[81](index=81&type=chunk) - The company's product quality system fully aligns with international standards, holding market access qualifications for multiple countries including EU CE, US FDA, Canada, Brazil, and Australia, and is among the first global medical device manufacturers to comply with both EU IVDR and MDR requirements[82](index=82&type=chunk) - The company has a R&D team of nearly **300** technical engineers; as of June 30, 2025, it holds **108** valid domestic patents (**52** invention patents), **174** trademark registrations, and **179** software copyrights, actively extending its IVD focus towards molecular diagnostics[83](index=83&type=chunk) [III. Analysis of Main Business](index=24&type=section&id=III.%20Analysis%20of%20Main%20Business) Operating revenue decreased by **21.22%** year-on-year, while financial expenses significantly dropped by **62.40%** due to reduced interest costs Year-on-Year Changes in Key Financial Data | Indicator | Current Period (RMB) | Prior Year (RMB) | Year-on-Year Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 230,956,513.82 | 293,161,345.69 | -21.22% | | | Operating Cost | 135,389,759.37 | 178,001,930.88 | -23.94% | | | Selling Expenses | 32,409,165.20 | 38,929,121.82 | -16.75% | | | Administrative Expenses | 39,252,396.46 | 46,306,139.37 | -15.23% | | | Financial Expenses | 1,975,737.22 | 5,254,391.49 | -62.40% | Reduced interest expenses during the reporting period | | Income Tax Expense | 3,396,273.71 | 1,367,951.21 | 148.27% | Supplementary corporate income tax paid during the reporting period | | R&D Investment | 11,712,995.01 | 14,112,890.95 | -17.00% | | | Net Cash Flow from Operating Activities | 17,107,755.47 | 17,229,405.33 | -0.71% | | | Net Cash Flow from Investing Activities | -27,136,509.11 | 1,378,111.68 | -2,069.11% | Unmatured structured deposits during the reporting period | | Net Cash Flow from Financing Activities | -116,433,784.00 | -62,322,354.45 | -86.83% | Reduced bank borrowings during the reporting period | | Net Increase in Cash and Cash Equivalents | -125,960,970.93 | -42,842,413.15 | -194.01% | Reduced bank borrowings during the reporting period | Products or Services Accounting for Over 10% of Revenue | Product or Service | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Margin | Operating Revenue Change from Prior Year | Operating Cost Change from Prior Year | Gross Margin Change from Prior Year | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Vacuum Blood Collection System | 153,536,093.10 | 88,325,865.45 | 42.47% | -14.73% | -14.55% | -0.12% | | Reagents | 28,249,854.64 | 15,109,667.49 | 46.51% | -26.30% | -35.13% | 7.28% | | Software Products and Services | 23,170,670.68 | 15,220,305.81 | 34.31% | -31.50% | -36.96% | 5.69% | - There were no significant changes in the company's profit composition or sources during the reporting period[86](index=86&type=chunk) [IV. Analysis of Non-Core Business](index=25&type=section&id=IV.%20Analysis%20of%20Non-Core%20Business) Non-core businesses significantly contributed to total profit, with investment income accounting for **58.33%**, primarily from equity-accounted associate investments Non-Core Business Analysis | Item | Amount (RMB) | Proportion of Total Profit | Reason for Formation | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 10,984,135.17 | 58.33% | Investment income recognized from associates accounted for using the equity method | Profit/loss of investees accounted for using the equity method is sustainable | | Gains/losses from changes in fair value | 0.00 | 0.00% | | | | Asset Impairment | -34,052.00 | -0.18% | Provision for bad debts on contract assets | No | | Non-operating Income | 1,354,182.69 | 7.19% | Mainly non-payable amounts | No | | Non-operating Expenses | 786,956.28 | 4.18% | Mainly asset disposal losses | No | | Other Income | 2,923,858.14 | 15.53% | Amortization of deferred income and VAT refunds for software products | No | | Credit Impairment Loss | -1,535,719.03 | -8.16% | Provision for bad debts | Yes | [V. Analysis of Assets and Liabilities](index=26&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) Total assets decreased by **10.09%** year-on-year, while net assets attributable to shareholders increased by **2.52%**, with significant reductions in cash, short-term, and long-term borrowings Significant Changes in Asset Composition | Item | Current Period-End Amount (RMB) | Proportion of Total Assets | Prior Year-End Amount (RMB) | Proportion of Total Assets | Proportion Change | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Cash and Bank Balances | 121,988,050.04 | 10.91% | 247,949,011.09 | 19.93% | -9.02% | Reduced loan scale, repaid bank borrowings with own funds | | Accounts Receivable | 140,686,107.37 | 12.58% | 158,069,595.31 | 12.71% | -0.13% | | | Inventories | 101,064,031.07 | 9.03% | 102,879,565.59 | 8.27% | 0.76% | | | Long-term Equity Investments | 109,826,401.91 | 9.82% | 107,558,236.44 | 8.65% | 1.17% | | | Fixed Assets | 281,918,276.17 | 25.20% | 291,228,641.49 | 23.41% | 1.79% | | | Construction in Progress | 83,638,762.00 | 7.48% | 80,540,596.79 | 6.47% | 1.01% | | | Short-term Borrowings | 196,315,959.88 | 17.55% | 282,020,746.98 | 22.67% | -5.12% | Reduced loan scale, repaid bank borrowings with own funds | | Long-term Borrowings | 28,355,286.67 | 2.53% | 51,717,638.34 | 4.16% | -1.63% | Reduced loan scale, repaid bank borrowings with own funds | Financial Assets Measured at Fair Value | Item | Beginning Balance (RMB) | Amount Purchased in Current Period (RMB) | Amount Sold in Current Period (RMB) | Ending Balance (RMB) | | :--- | :--- | :--- | :--- | :--- | | Financial assets held for trading (excluding derivative financial assets) | | 132,850,000.00 | 109,850,000.00 | 23,000,000.00 | | Other equity instrument investments | 16,139,800.00 | | | 16,139,800.00 | | Other non-current financial assets | 59,300,800.00 | | | 59,300,800.00 | | Subtotal of Financial Assets | 75,440,600.00 | 132,850,000.00 | 109,850,000.00 | 98,440,600.00 | - As of the end of the reporting period, the total book value of restricted assets amounted to **RMB 87,490,662.94**, primarily comprising cash and bank balances, intangible assets, and construction in progress pledged or mortgaged[95](index=95&type=chunk) [VI. Analysis of Investment Status](index=27&type=section&id=VI.%20Analysis%20of%20Investment%20Status) The company had no significant equity or non-equity investments, with financial assets measured at fair value totaling **RMB 98,440,600.00** from own funds Financial Assets Measured at Fair Value | Asset Category | Initial Investment Cost (RMB) | Amount Purchased in Current Period (RMB) | Amount Sold in Current Period (RMB) | Ending Balance (RMB) | Source of Funds | | :--- | :--- | :--- | :--- | :--- | :--- | | Financial Assets Held for Trading | | 132,850,000.00 | 109,850,000.00 | 23,000,000.00 | Own Funds | | Other Equity Instrument Investments | 16,139,800.00 | | | 16,139,800.00 | Own Funds | | Other Non-current Financial Assets | 59,300,800.00 | | | 59,300,800.00 | Own Funds | | Total | 75,440,600.00 | 132,850,000.00 | 109,850,000.00 | 98,440,600.00 | -- | - The company had no use of raised funds during the reporting period[98](index=98&type=chunk) - The company had no entrusted wealth management, derivative investments, or entrusted loans during the reporting period[99](index=99&type=chunk)[100](index=100&type=chunk)[101](index=101&type=chunk) [VII. Significant Asset and Equity Sales](index=28&type=section&id=VII.%20Significant%20Asset%20and%20Equity%20Sales) During the reporting period, the company did not engage in any significant asset or equity sales - The company did not sell any significant assets during the reporting period[102](index=102&type=chunk) - The company did not sell any significant equity during the reporting period[103](index=103&type=chunk) [VIII. Analysis of Major Holding and Participating Companies](index=28&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) Net profit of Guangzhou Improve Medical Instruments Co., Ltd. increased, and Shenzhen Yanghe Biomedical Industry Investment Co., Ltd. saw significant profit growth, while two subsidiaries were deregistered Major Subsidiaries and Associates with Over 10% Impact on Company's Net Profit | Company Name | Company Type | Registered Capital (RMB) | Total Assets (RMB) | Net Assets (RMB) | Operating Revenue (RMB) | Operating Profit (RMB) | Net Profit (RMB) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Guangzhou Improve Medical Instruments Co., Ltd. | Subsidiary | 100,000,000.00 | 243,604,356.37 | 62,092,819.29 | 114,712,795.23 | 7,174,480.20 | 6,483,760.87 | | Guangzhou Improve Bay Innovation Enterprise Incubator Co., Ltd. | Subsidiary | 30,000,000.00 | 26,965,567.01 | 26,669,844.54 | 617,923.68 | -1,557,143.69 | -1,593,604.40 | | Nanxiong Improve Medical Technology Co., Ltd. | Subsidiary | 25,000,000.00 | 49,553,255.07 | 45,644,376.72 | 21,851,403.94 | 5,564,171.80 | 2,953,358.17 | | Guangdong Improve Smart Medical Information Technology Co., Ltd. and its subsidiaries | Subsidiary | 10,000,000.00 | 97,990,691.48 | -26,936,250.79 | 25,474,660.80 | -1,580,511.18 | -1,574,756.91 | | Shenzhen Yanghe Biomedical Industry Investment Co., Ltd. | Associate | 151,136,400.00 | 291,545,845.60 | 242,185,107.53 | 226,415.04 | 36,575,283.52 | 28,979,177.90 | - Guangzhou Improve Medical Instruments Co., Ltd.'s net profit for the current period was **RMB 6,483,760.87**, an increase of **RMB 2,327,092.99** from the prior year, mainly due to reduced period expenses[107](index=107&type=chunk) - Shenzhen Yanghe Biomedical Industry Investment Co., Ltd.'s net profit for the current period was **RMB 28,979,177.90**, an increase of **RMB 62,166,584.93** from the prior year, primarily due to increased fair value change gains recognized from investments in listed company shares[107](index=107&type=chunk) - During the reporting period, the company deregistered Guangzhou Improve Smart Medical Technology Co., Ltd. and Guangzhou Ruida Medical Instruments Co., Ltd.[106](index=106&type=chunk) [IX. Structured Entities Controlled by the Company](index=30&type=section&id=IX.%20Structured%20Entities%20Controlled%20by%20the%20Company) The company did not control any structured entities during the reporting period - The company did not control any structured entities during the reporting period[108](index=108&type=chunk) [X. Risks Faced by the Company and Countermeasures](index=30&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces risks from policy changes, new product R&D, overseas sales, market competition, and talent retention, actively implementing various countermeasures - Industry policy change risk: Centralized volume-based procurement may increase sales but reduce profits; the company responds by winning bids, reducing costs, improving efficiency, and refining its distributor system[108](index=108&type=chunk)[109](index=109&type=chunk) - New product and technology R&D risk: R&D may face technical difficulties, delays, or failures due to policy or market factors; the company responds through independent R&D and strengthened cooperation with research institutions and international peers[110](index=110&type=chunk) - Overseas market sales risk: Global political and economic uncertainties, trade barriers, and exchange rate fluctuations may impact overseas sales; the company responds by purchasing export credit insurance and establishing localized overseas production[111](index=111&type=chunk) - Increased market competition risk: The in-vitro diagnostics industry is highly competitive; the company needs to maintain advantages in cost, technology, brand, and customer trust, shifting from product competition to comprehensive solution competition[112](index=112&type=chunk) - Talent and technology reserve risk: High talent mobility and fierce competition; the company retains and attracts talent by offering competitive compensation, improving intellectual property management, and planning incentive schemes[113](index=113&type=chunk)[114](index=114&type=chunk) [XI. Registration Form for Investor Relations Activities During the Reporting Period](index=32&type=section&id=XI.%20Registration%20Form%20for%20Investor%20Relations%20Activities%20During%20the%20Reporting%20Period) The company did not engage in any investor relations activities such as research visits, communications, or interviews during the reporting period - The company did not engage in any investor relations activities such as research visits, communications, or interviews during the reporting period[115](index=115&type=chunk) [XII. Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan](index=32&type=section&id=XII.%20Formulation%20and%20Implementation%20of%20Market%20Value%20Management%20System%20and%20Valuation%20Enhancement%20Plan) The company has not formulated a market value management system nor disclosed a valuation enhancement plan - The company has not formulated a market value management system[116](index=116&type=chunk) - The company has not disclosed a valuation enhancement plan[116](index=116&type=chunk) [XIII. Implementation of "Quality and Return Dual Improvement" Action Plan](index=32&type=section&id=XIII.%20Implementation%20of%20%22Quality%20and%20Return%20Dual%20Improvement%22%20Action%20Plan) The company has not disclosed an announcement regarding the "Quality and Return Dual Improvement" action plan - The company has not disclosed an announcement regarding the 'Quality and Return Dual Improvement' action plan[116](index=116&type=chunk) [Section 4 Corporate Governance, Environment, and Society](index=33&type=section&id=Section%204%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) This section covers changes in directors, supervisors, and senior management, profit distribution, equity incentives, environmental disclosure, and social responsibility practices [I. Changes in Directors, Supervisors, and Senior Management](index=33&type=section&id=I.%20Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, Vice General Manager Xu Lixin was dismissed on February 28, 2025, due to personal reasons Changes in Directors, Supervisors, and Senior Management | Name | Position Held | Type | Date | Reason | | :--- | :--- | :--- | :--- | :--- | | Xu Lixin | Vice General Manager | Dismissal | February 28, 2025 | Personal reasons | [II. Profit Distribution and Capital Reserve Conversion to Share Capital in Current Period](index=33&type=section&id=II.%20Profit%20Distribution%20and%20Capital%20Reserve%20Conversion%20to%20Share%20Capital%20in%20Current%20Period) The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the half-year - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the half-year[119](index=119&type=chunk) [III. Implementation of Company Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=33&type=section&id=III.%20Implementation%20of%20Company%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period[120](index=120&type=chunk) [IV. Environmental Information Disclosure](index=33&type=section&id=IV.%20Environmental%20Information%20Disclosure) The listed company and its main subsidiaries are not included in the list of enterprises required to disclose environmental information by law - The listed company and its main subsidiaries are not included in the list of enterprises required to disclose environmental information by law[121](index=121&type=chunk) [V. Social Responsibility](index=33&type=section&id=V.%20Social%20Responsibility) The company actively fulfills social responsibilities by enhancing governance, ensuring fair disclosure, protecting stakeholder rights, prioritizing employee well-being, maintaining product quality, and promoting environmental protection - The company strictly adheres to laws and regulations, improves corporate governance and internal controls, protects shareholder and creditor rights, and ensures fair information disclosure through investor hotlines, mailboxes, and interactive platforms[122](index=122&type=chunk)[123](index=123&type=chunk)[124](index=124&type=chunk)[125](index=125&type=chunk)[126](index=126&type=chunk) - The company prioritizes employee health and safety, offering free medical examinations, establishing safety management bodies, implementing a full-staff safety production responsibility system, and conducting various safety education and emergency drills, with no general or higher-level safety production accidents during the reporting period[128](index=128&type=chunk)[129](index=129&type=chunk) - The company maintains robust labor protection, legally signing labor contracts, paying social insurance and housing provident funds, improving compensation systems and talent development mechanisms, and building an efficient and comprehensive capacity-building and education training system[131](index=131&type=chunk)[132](index=132&type=chunk)[133](index=133&type=chunk) - The company considers product quality its lifeline, providing excellent medical solutions and service experiences, and deepens cooperation with suppliers based on principles of 'equality, trust, mutual benefit, and efficient communication,' implementing a transparent procurement policy[136](index=136&type=chunk)[138](index=138&type=chunk) - The company highly values environmental management, allocating special funds for environmental protection, promoting equipment upgrades and optimized production processes for resource conservation, and establishing comprehensive management systems for hazardous waste, industrial solid waste, and medical waste to ensure compliance with discharge standards[139](index=139&type=chunk)[140](index=140&type=chunk)[141](index=141&type=chunk) - The company pays taxes according to law, actively participates in social welfare activities such as charity visits and Arbor Day events, and launched the 'May 15 National Investor Protection Publicity Day' to disseminate financial knowledge and rational investment concepts[143](index=143&type=chunk)[144](index=144&type=chunk)[145](index=145&type=chunk) [Section 5 Significant Matters](index=38&type=section&id=Section%205%20Significant%20Matters) This section covers the absence of major commitments, non-operating fund occupation, illegal guarantees, bankruptcy, penalties, and integrity issues, detailing litigation, related party transactions, and subsidiary matters [I. Commitments Fulfilled or Overdue by Controlling Shareholder, Shareholders, Related Parties, Acquirers, and the Company During the Reporting Period](index=38&type=section&id=I.%20Commitments%20Fulfilled%20or%20Overdue%20by%20Controlling%20Shareholder%2C%20Shareholders%2C%20Related%20Parties%2C%20Acquirers%2C%20and%20the%20Company%20During%20the%20Reporting%20Period) During the reporting period, there were no fulfilled or overdue commitments by the company's actual controller, shareholders, related parties, acquirers, or the company - During the reporting period, there were no fulfilled or overdue commitments by the company's actual controller, shareholders, related parties, acquirers, or the company[147](index=147&type=chunk) [II. Non-Operating Fund Occupation by Controlling Shareholder and Other Related Parties](index=38&type=section&id=II.%20Non-Operating%20Fund%20Occupation%20by%20Controlling%20Shareholder%20and%20Other%20Related%20Parties) During the reporting period, there was no non-operating fund occupation by the controlling shareholder or other related parties of the listed company - During the reporting period, there was no non-operating fund occupation by the controlling shareholder or other related parties of the listed company[148](index=148&type=chunk) [III. Irregular External Guarantees](index=38&type=section&id=III.%20Irregular%20External%20Guarantees) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[149](index=149&type=chunk) [IV. Appointment and Dismissal of Accounting Firms](index=38&type=section&id=IV.%20Appointment%20and%20Dismissal%20of%20Accounting%20Firms) The company's semi-annual report was not audited - The company's semi-annual report was not audited[150](index=150&type=chunk) [V. Explanations by the Board of Directors, Supervisory Board, and Audit Committee on the Accounting Firm's "Non-Standard Audit Report" for the Current Period](index=38&type=section&id=V.%20Explanations%20by%20the%20Board%20of%20Directors%2C%20Supervisory%20Board%2C%20and%20Audit%20Committee%20on%20the%20Accounting%20Firm%27s%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Current%20Period) During the reporting period, there were no explanations from the Board, Supervisory Board, or Audit Committee regarding a "non-standard audit report" - During the reporting period, there were no explanations from the Board of Directors, Supervisory Board, or Audit Committee regarding a 'non-standard audit report' from the accounting firm[151](index=151&type=chunk) [VI. Board of Directors' Explanation on "Non-Standard Audit Report" for the Prior Year](index=38&type=section&id=VI.%20Board%20of%20Directors%27%20Explanation%20on%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Prior%20Year) During the reporting period, there was no explanation from the Board of Directors regarding the prior year's "non-standard audit report" - During the reporting period, there was no explanation from the Board of Directors regarding the prior year's 'non-standard audit report'[151](index=151&type=chunk) [VII. Bankruptcy and Reorganization Matters](index=38&type=section&id=VII.%20Bankruptcy%20and%20Reorganization%20Matters) The company had no bankruptcy or reorganization matters during the reporting period - The company had no bankruptcy or reorganization matters during the reporting period[151](index=151&type=chunk) [VIII. Litigation Matters](index=38&type=section&id=VIII.%20Litigation%20Matters) The company had no major litigation or arbitration during the period, but is involved in several finance lease lawsuits as plaintiff, with **RMB 20.2597 million** in other pending cases - The company had no major litigation or arbitration matters during the current reporting period[152](index=152&type=chunk) - The company's subsidiary, Improve Run, is involved as plaintiff in multiple finance lease lawsuits; some cases have been won and entered enforcement, with **RMB 2.9758 million** recovered in one case[153](index=153&type=chunk) - Excluding the above, other litigation cases involving the company during the reporting period totaled **RMB 20.2597 million**, of which **RMB 19.6050 million** remains unresolved, but is not expected to create new provisions[154](index=154&type=chunk) [IX. Penalties and Rectification](index=39&type=section&id=IX.%20Penalties%20and%20Rectification) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period[155](index=155&type=chunk) [X. Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=39&type=section&id=X.%20Integrity%20Status%20of%20the%20Company%2C%20its%20Controlling%20Shareholder%2C%20and%20Actual%20Controller) During the reporting period, there were no integrity issues concerning the company, its controlling shareholder, or actual controller - During the reporting period, there were no integrity issues concerning the company, its controlling shareholder, or actual controller[156](index=156&type=chunk) [XI. Significant Related Party Transactions](index=40&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) The company had no significant related party transactions during the reporting period, including those related to daily operations, asset/equity acquisitions/disposals, joint investments, or debt/credit - The company had no related party transactions related to daily operations during the reporting period[157](index=157&type=chunk) - The company had no related party transactions involving asset or equity acquisition/disposal during the reporting period[158](index=158&type=chunk) - The company had no related party debt or credit transactions during the reporting period[160](index=160&type=chunk) - The company had no other significant related party transactions during the reporting period[163](index=163&type=chunk) [XII. Significant Contracts and Their Performance](index=40&type=section&id=XII.%20Significant%20Contracts%20and%20Their%20Performance) The company had no entrustment, contracting, leasing, or significant guarantee matters, nor other major contracts during the reporting period - The company had no entrustment situations during the reporting period[164](index=164&type=chunk) - The company had no contracting situations during the reporting period[166](index=166&type=chunk) - The company had no leasing situations during the reporting period[167](index=167&type=chunk) - The company had no significant guarantee situations during the reporting period[168](index=168&type=chunk) - The company had no other significant contracts during the reporting period[170](index=170&type=chunk) [XIII. Explanation of Other Significant Matters](index=41&type=section&id=XIII.%20Explanation%20of%20Other%20Significant%20Matters) The controlling shareholder's upper-level equity structure is changing, but the controlling shareholder and actual controller remain unchanged; a wholly-owned subsidiary is being deregistered without significant impact - The controlling shareholder's upper-level equity structure is expected to change, with Zhuhai Science and Technology Industrial Group Co., Ltd. becoming a shareholder of Gree Financial Investment, but the company's controlling shareholder and actual controller remain unchanged, with no substantial impact on production and operations[171](index=171&type=chunk) - The company has approved and is processing the deregistration of its wholly-owned subsidiary, Improve Medical (Chenzhou) Co., Ltd., as its health industrial park project has terminated, and this deregistration will not significantly impact the company's overall business development and profitability[172](index=172&type=chunk)[173](index=173&type=chunk) [XIV. Significant Matters of Company Subsidiaries](index=42&type=section&id=XIV.%20Significant%20Matters%20of%20Company%20Subsidiaries) Improve Medical (Hunan) Co., Ltd. obtained medical device operating licenses, and Nanxiong Improve Medical Technology Co., Ltd. secured a drug manufacturing license, providing future production qualifications - Improve Medical (Hunan) Co., Ltd. obtained a 'Medical Device Business License' and a 'Class II Medical Device Business Filing Certificate,' allowing it to conduct wholesale and retail medical device business within its scope[174](index=174&type=chunk) - Nanxiong Improve Medical Technology Co., Ltd. obtained its first 'Drug Manufacturing License,' providing qualification for future commercial drug production, though related products still require drug marketing authorization numbers and are not expected to significantly impact current company performance[175](index=175&type=chunk) [Section 6 Share Changes and Shareholder Information](index=43&type=section&id=Section%206%20Share%20Changes%20and%20Shareholder%20Information) This section details share changes, securities issuance, shareholder information, director/supervisor/senior management shareholdings, and changes in controlling shareholder or actual controller [I. Share Change Status](index=43&type=section&id=I.%20Share%20Change%20Status) Restricted shares decreased by **12,301,376**, while unrestricted shares increased by the same amount, with total shares unchanged, mainly due to executive share release and one executive's departure Share Change Status | Item | Quantity Before Change (Shares) | Proportion | Net Increase/Decrease in Current Change (Shares) | Quantity After Change (Shares) | Proportion | | :--- | :--- | :--- | :--- | :--- | :--- | | I. Restricted Shares | 49,262,641 | 15.93% | -12,301,376 | 36,961,265 | 11.95% | | II. Unrestricted Shares | 259,924,674 | 84.07% | 12,301,376 | 272,226,050 | 88.05% | | III. Total Shares | 309,187,315 | 100.00% | 0 | 309,187,315 | 100.00% | - Restricted shares held by executives Deng Guanhua, Zhang Wen, and Xu Guangzhi were released, increasing unrestricted shares[178](index=178&type=chunk)[179](index=179&type=chunk) - Mr. Xu Lixin's shares were fully locked as he resigned from senior management less than 6 months ago, resulting in an increase of **1,500** restricted shares[179](index=179&type=chunk) Changes in Restricted Shares | Shareholder Name | Beginning Restricted Shares (Shares) | Shares Released from Restriction in Current Period (Shares) | Shares Added to Restriction in Current Period (Shares) | Ending Restricted Shares (Shares) | Reason for Restriction | Planned Release Date | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Deng Guanhua | 49,194,555 | 12,298,639 | | 36,895,916 | Executive Restricted Shares | According to regulations on executive share management | | Yan Hongyu | 21,937 | | | 21,937 | Executive Restricted Shares | According to regulations on executive share management | | Xu Lixin | 4,500 | | 1,500 | 6,000 | Executive Restricted Shares | According to regulations on executive share management | | Xu Guangzhi | 50 | 13 | | 37 | Executive Restricted Shares | According to regulations on executive share management | | Zhang Hong | 24,705 | | | 24,705 | Executive Restricted Shares | According to regulations on executive share management | | Zhang Wen | 16,894 | 4,224 | | 12,670 | Executive Restricted Shares | According to regulations on executive share management | | Total | 49,262,641 | 12,302,876 | 1,500 | 36,961,265 | -- | -- | [II. Securities Issuance and Listing](index=44&type=section&id=II.%20Securities%20Issuance%20and%20Listing) The company had no securities issuance or listing activities during the reporting period - The company had no securities issuance or listing activities during the reporting period[182](index=182&type=chunk) [III. Number of Shareholders and Shareholding Status](index=44&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Status) As of the reporting period end, total common shareholders were **24,417**; Deng Guanhua held **15.91%** (all pledged), and Zhuhai Gree Financial Investment Management Co., Ltd. held **10.84%** as controlling shareholder - The total number of common shareholders at the end of the reporting period was **24,417**[183](index=183&type=chunk) Shareholding Status of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Proportion | Shares Held at Period-End (Shares) | Restricted Shares Held (Shares) | Unrestricted Shares Held (Shares) | Pledged, Marked, or Frozen Status | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Deng Guanhua | Domestic Natural Person | 15.91% | 49,194,555 | 36,895,916 | 12,298,639 | Pledged 49,194,555 | | Zhuhai Gree Financial Investment Management Co., Ltd. | State-owned Legal Person | 10.84% | 33,528,364 | 0 | 33,528,364 | N/A 0 | | Zhao Jiqing | Domestic Natural Person | 4.95% | 15,300,000 | 0 | 15,300,000 | Frozen 5,600,000 | - Mr. Deng Guanhua and Mr. Zhao Jiqing have irrevocably waived their voting rights for all company shares held, and the waiver period has been extended by **24** months[185](index=185&type=chunk) [IV. Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=46&type=section&id=IV.%20Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) There were no changes in the shareholdings of the company's directors, supervisors, and senior management during the reporting period - There were no changes in the shareholdings of the company's directors, supervisors, and senior management during the reporting period; refer to the 2024 annual report for details[186](index=186&type=chunk) [V. Changes in Controlling Shareholder or Actual Controller](index=46&type=section&id=V.%20Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) The company's controlling shareholder and actual controller remained unchanged during the reporting period - The company's controlling shareholder remained unchanged during the reporting period[187](index=187&type=chunk) - The company's actual controller remained unchanged during the reporting period[187](index=187&type=chunk) [Section 7 Bond-Related Information](index=48&type=section&id=Section%207%20Bond-Related%20Information) This section confirms the absence of any bond-related information for the company during the reporting period [Bond-Related Information](index=48&type=section&id=Bond-Related%20Information) The company had no bond-related information during the reporting period - The company had no bond-related information during the reporting period[191](index=191&type=chunk) [Section 8 Financial Report](index=49&type=section&id=Section%208%20Financial%20Report) This section presents the unaudited financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in equity, along with detailed notes on accounting policies, taxes, and other financial disclosures [I. Audit Report](index=49&type=section&id=I.%20Audit%20Report) The company's semi-annual financial report was not audited - The company's semi-annual financial report was not audited[193](index=193&type=chunk) [II. Financial Statements](index=49&type=section&id=II.%20Financial%20Statements) This section presents the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in equity for H1 2025 [1. Consolidated Balance Sheet](index=49&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of June 30, 2025, consolidated total assets were **RMB 1,118,593,526.11**, a **10.09%** decrease from the beginning of the period - As of June 30, 2025, consolidated total assets were **RMB 1,118,593,526.11**, a **10.09%** decrease from the beginning balance of **RMB 1,244,146,915.63**[196](index=196&type=chunk) - Total current assets were **RMB 467,611,047.31**, and total non-current assets were **RMB 650,982,478.80**[195](index=195&type=chunk)[196](index=196&type=chunk) - Total liabilities were **RMB 462,341,798.16**, and total owners' equity was **RMB 656,251,727.95**[198](index=198&type=chunk) [2. Parent Company Balance Sheet](index=51&type=section&id=2.%20Parent%20Company%20Balance%20Sheet) As of June 30, 2025, parent company total assets were **RMB 1,104,554,302.12**, a **9.31%** decrease from the beginning of the period - As of June 30, 2025, parent company total assets were **RMB 1,104,554,302.12**, a **9.31%** decrease from the beginning balance of **RMB 1,217,986,886.45**[200](index=200&type=chunk) - Total current assets were **RMB 382,403,732.48**, and total non-current assets were **RMB 722,150,569.64**[199](index=199&type=chunk)[200](index=200&type=chunk) - Total liabilities were **RMB 415,235,055.19**, and total owners' equity was **RMB 689,319,246.93**[200](index=200&type=chunk) [3. Consolidated Income Statement](index=53&type=section&id=3.%20Consolidated%20Income%20Statement) For H1 2025, consolidated operating revenue was **RMB 230,956,513.82**, down **21.22%** year-on-year, with net profit attributable to parent company shareholders increasing **389.40%** to **RMB 15,266,563.13** - For H1 2025, consolidated operating revenue was **RMB 230,956,513.82**, a **21.22%** decrease from **RMB 293,161,345.69** in the prior year[202](index=202&type=chunk)[203](index=203&type=chunk) - Consolidated net profit was **RMB 15,435,311.32**, with net profit attributable to parent company shareholders at **RMB 15,266,563.13**, a significant **389.40%** increase from **RMB -5,275,309.54** in the prior year[203](index=203&type=chunk) - Basic earnings per share improved significantly to **RMB 0.05** from **RMB -0.02** in the prior year[204](index=204&type=chunk) [4. Parent Company Income Statement](index=55&type=section&id=4.%20Parent%20Company%20Income%20Statement) For H1 2025, parent company operating revenue was **RMB 113,286,358.86**, down **23.25%** year-on-year, achieving a net profit of **RMB 2,328,404.14** from a prior year loss - For H1 2025, parent company operating revenue was **RMB 113,286,358.86**, a **23.25%** decrease from **RMB 147,601,358.44** in the prior year[206](index=206&type=chunk) - Parent company net profit was **RMB 2,328,404.14**, turning a profit from a **RMB -6,577,107.28** loss in the prior year[207](index=207&type=chunk) [5. Consolidated Cash Flow Statement](index=56&type=section&id=5.%20Consolidated%20Cash%20Flow%20Statement) For H1 2025, net cash flow from operating activities was **RMB 17,107,755.47**, while investing activities saw a net outflow of **RMB 27,136,509.11** due to unmatured deposits - Net cash flow from operating activities was **RMB 17,107,755.47**, a slight decrease of **0.71%** year-on-year[209](index=209&type=chunk) - Net cash flow from investing activities was **RMB -27,136,509.11**, a significant **2,069.11%** decrease year-on-year, primarily due to unmatured structured deposits during the reporting period[209](index=209&type=chunk) - Net cash flow from financing activities was **RMB -116,433,784.00**, an **86.83%** decrease year-on-year, primarily due to reduced bank borrowings during the reporting period[209](index=209&type=chunk) [6. Parent Company Cash Flow Statement](index=57&type=section&id=6.%20Parent%20Company%20Cash%20Flow%20Statement) For H1 2025, parent company net cash flow from operating activities increased by **79.49%** to **RMB 26,001,123.47**, with investing activities showing significant improvement - Net cash flow from operating activities was **RMB 26,001,123.47**, a **79.49%** increase from **RMB 14,486,384.62** in the prior year[211](index=211&type=chunk) - Net cash flow from investing activities was **RMB 27,369,653.80**, a significant improvement from **RMB -45,819,166.92** in the prior year[211](index=211&type=chunk) - Net cash flow from financing activities was **RMB -153,707,865.19**, a **194.01%** decrease from **RMB -48,953,266.79** in the prior year[211](index=211&type=chunk) [7. Consolidated Statement of Changes in Owners' Equity](index=59&type=section&id=7.%20Consolidated%20Statement%20of%20Changes%20in%20Owners%27%20Equity) As of June 30, 2025, consolidated owners' equity totaled **RMB 656,251,727.95**, an increase of **RMB 12,386,841.99** from the beginning of the period - As of June 30, 2025, consolidated owners' equity totaled **RMB 656,251,727.95**, an increase of **RMB 12,386,841.99** from the beginning balance of **RMB 643,864,885.96**[215](index=215&type=chunk) - Total comprehensive income attributable to owners of the parent company was **RMB 15,270,593.80**[215](index=215&type=chunk) - Distributions to minority shareholders decreased by **RMB 3,052,500.00**[215](index=215&type=chunk) [8. Parent Company Statement of Changes in Owners' Equity](index=62&type=section&id=8.%20Parent%20Company%20Statement%20of%20Changes%20in%20Owners%27%20Equity) As of June 30, 2025, parent company owners' equity totaled **RMB 689,319,246.93**, an increase of **RMB 2,328,404.14** from the beginning of the period - As of June 30, 2025, parent company owners' equity totaled **RMB 689,319,246.93**, an increase of **RMB 2,328,404.14** from the beginning balance of **RMB 686,990,842.79**[223](index=223&type=chunk) - Total comprehensive income for the current period was **RMB 2,328,404.14**[223](index=223&type=chunk) [III. Company Basic Information](index=65&type=section&id=III.%20Company%20Basic%20Information) Improve Medical Instruments Co., Ltd., established on August 19, 1996, listed on Shenzhen Stock Exchange (300030) in 2009, with registered capital of **RMB 309,187,315.00** - Improve Medical Instruments Co., Ltd. was established on August 19, 1996, and listed on the ChiNext board of the Shenzhen Stock Exchange on December 25, 2009, with stock code **300030**[227](index=227&type=chunk)[228](index=228&type=chunk) - As of the end of the reporting period, the company's total issued share capital was **309,187,315.00 shares**, and its registered capital was **RMB 309,187,315.00**[232](index=232&type=chunk) - The company's main business activities include manufacturing medical laboratory equipment and instruments, operating licensed medical devices, software development, and information system integration services[234](index=234&type=chunk) [IV. Basis of Financial Statement Preparation](index=66&type=section&id=IV.%20Basis%20of%20Financial%20Statement%20Preparation) The financial statements are prepared on a going concern basis, adhering to Enterprise Accounting Standards and CSRC disclosure rules, with no identified issues affecting the company's ability to continue as a going concern for the next 12 months - The company prepares its financial statements on a going concern basis, recognizing and measuring transactions and events in accordance with Enterprise Accounting Standards, their application guidelines, and interpretations[236](index=236&type=chunk) - The company also discloses relevant financial information in accordance with the China Securities Regulatory Commission's 'Reporting Rules for Information Disclosure by Companies Issuing Securities to the Public No. 15 – General Provisions for Financial Reports (Revised 2023)'[236](index=236&type=chunk) - The company assessed its ability to continue as a going concern for 12 months from the end of the reporting period and found no matters affecting this ability[237](index=237&type=chunk) [V. Significant Accounting Policies and Estimates](index=66&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section details the company's significant accounting policies and estimates, covering financial statement preparation, asset and liability recognition, revenue, government grants, deferred income tax, and ongoing assessment of key estimates like goodwill impairment - The company adheres to Enterprise Accounting Standards, prepares financial statements on a going concern basis, and uses RMB as its functional currency[239](index=239&type=chunk)[242](index=242&type=chunk) - Detailed accounting methods for business combinations under common control and non-common control are provided, along with consolidation methods and criteria for determining the scope of consolidation[244](index=244&type=chunk)[245](index=245&type=chunk)[248](index=248&type=chunk)[249](index=249&type=chunk) - Financial instruments are classified as measured at amortized cost, fair value through profit or loss, or fair value through other comprehensive income, with specific measurement methods for impairment provisions, especially the expected credit loss model[270](index=270&type=chunk)[271](index=271&type=chunk)[272](index=272&type=chunk)[273](index=273&type=chunk)[276](index=276&type=chunk)[277](index=277&type=chunk) - Revenue is recognized when the customer obtains control of the related goods, distinguishing between obligations satisfied over time or at a point in time based on the nature of the performance obligation[352](index=352&type=chunk)[353](index=353&type=chunk)[354](index=354&type=chunk) - The company continuously assesses significant accounting estimates and key assumptions, particularly goodwill impairment and

天眼查商业履历信息显示，阳普医疗科技股份有限公司，成立于1996年，位于珠海市，是一家以从事专 用设备制造业为主的企业。企业注册资本30918.7315万人民币，实缴资本4880万人民币。公司法定代表 人为杨涛。 通过天眼查大数据分析，阳普医疗科技股份有限公司共对外投资了17家企业，参与招投标项目383次， 知识产权方面有商标信息136条，专利信息179条，此外企业还拥有行政许可135个。 金融界消息 截至2025年8月13日收盘，阳普医疗（300030）报收于8.87元，下跌2.85%，换手率 12.18%，成交量31.66万手，成交金额2.82亿元。 资金流向方面，今日主力资金净流出3634.97万元，占比成交额12.89%。其中，超大单净流出1223.98万 元、占成交额4.34%，大单净流出2410.99万元、占成交额8.55%，中单净流出流入1042.33万元、占成交 额3.7%，小单净流入2592.64万元、占成交额9.19%。 阳普医疗最新一期业绩显示，截至2025一季报，公司营业总收入1.16亿元、同比减少18.15%，归属净利 润780.84万元，同比增长344.71%，扣非净利润729.8 ...

Group 1 - The stock price of Yangpu Medical reached 9.13 yuan as of August 12, 2025, with an increase of 1.90% compared to the previous trading day [1] - The opening price was 9.04 yuan, with a daily high of 9.50 yuan and a low of 8.95 yuan, resulting in a trading volume of 386,300 hands and a transaction amount of 356 million yuan [1] - Yangpu Medical operates in the medical device industry, focusing on in vitro diagnostics and medical equipment, and does not currently engage in original research drug-related businesses [1] Group 2 - On August 12, the net inflow of main funds was 19.32 million yuan, accounting for 0.81% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds was 34.77 million yuan, representing 1.47% of the circulating market value [1]

Company Overview - Yangpu Medical's stock price as of August 8, 2025, is 8.98 yuan, down 0.31 yuan from the previous trading day's closing price, representing a decline of 3.34% [1] - The company operates in the medical device industry, focusing on in vitro diagnostics and medical equipment, with registered operations in Guangdong Province [1] - Yangpu Medical is involved in CAR-T cell therapy and internet healthcare [1] Stock Performance - On August 8, the stock opened at 9.12 yuan, reached a high of 9.57 yuan, and a low of 8.84 yuan, with a trading volume of 500,453 hands and a transaction amount of 456 million yuan [1] - The stock experienced a rapid rebound, reaching 9.08 yuan at 10:03 AM, with a gain of over 2% within five minutes and a transaction amount of 185 million yuan during that period [1] Capital Flow - On August 8, the net outflow of main funds for Yangpu Medical was 37.115 million yuan, accounting for 1.59% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 60.302 million yuan, representing 2.58% of the circulating market value [1]

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为3%、71%、23%、3%。其 中，获得博士学历的CFO仅一人，为阳普医疗的闫红玉。 从薪酬分布看，A股医疗设备公司CFO年薪平均值为106.52万元。经统计，处于50万以下、50万-100 万、100万-200万、200万以上各区间的人数占比分别为31%、43%、20%、6%。 其中，年薪排行前三的CFO分别为迈瑞医疗的赵云、鱼跃医疗的刘丽华、万东医疗的井晓权，三人年薪 分别为841.34万元、431.36万元、164.12万元。 从薪酬变动幅度看（仅统计任职两年以上CFO薪资数据），2024年港通医疗的张秋薪酬降幅最大，同比 降幅达31.23%；麦澜德的徐宁薪酬增幅最大，同比涨幅达165.59%。 分行业来看，统计数据显示，剔除20 ...

Company Overview - Yangpu Medical's stock price closed at 8.56 yuan on August 6, down 0.31 yuan, a decrease of 3.49% from the previous trading day [1] - The stock reached a high of 9.06 yuan and a low of 8.52 yuan during the day, with an overall volatility of 6.09% and a trading volume of 262 million yuan [1] Industry Position - The company operates in the medical device industry, focusing on vacuum blood collection systems and in vitro diagnostics [1] - Yangpu Medical has made investments in innovative medical technologies, including CAR-T cell therapy, positioning itself within the Guangdong region's healthcare sector [1] Market Activity - On August 6, there was a net outflow of 12.4 million yuan in principal funds, with a cumulative net outflow of 11.56 million yuan over the past five trading days [1] - The stock experienced a rapid decline after the market opened, with a drop of over 2% within the first five minutes of trading [1]

天眼查商业履历信息显示，阳普医疗科技股份有限公司，成立于1996年，位于珠海市，是一家以从事专 用设备制造业为主的企业。企业注册资本30918.7315万人民币，实缴资本4880万人民币。公司法定代表 人为杨涛。 通过天眼查大数据分析，阳普医疗科技股份有限公司共对外投资了17家企业，参与招投标项目383次， 知识产权方面有商标信息136条，专利信息179条，此外企业还拥有行政许可135个。 来源：金融界 金融界消息 截至2025年8月5日收盘，阳普医疗（300030）报收于8.87元，下跌1.11%，换手率15.04%， 成交量39.09万手，成交金额3.43亿元。 资金流向方面，今日主力资金净流出2666.97万元，占比成交额7.77%。其中，超大单净流出1972.53万 元、占成交额5.75%，大单净流出694.44万元、占成交额2.02%，中单净流出流入1146.96万元、占成交 额3.34%，小单净流入1520.01万元、占成交额4.43%。 阳普医疗最新一期业绩显示，截至2025一季报，公司营业总收入1.16亿元、同比减少18.15%，归属净利 润780.84万元，同比增长344.71%，扣非净利润 ...